Table 3 Predictors of bleeding events (only in the DOAC+ group).
| Overall (N = 164) | Bleeding event+ (N = 10) | Bleeding event– (N = 154) | P value | |
|---|---|---|---|---|
| Age, years | 74 (73–76) | 76.8 (71.2–82.4) | 74.8 (73.4–76.2) | 0.522 |
| Female sex, n (%) | 145 (88.4%) | 9 (90.0%) | 136 (88.3%) | 0.719 |
| Body mass index | 24.4 (23.6–25.1) | 22.0 (20.5–23.6) | 24.6 (24.0–25.3) | 0.018 |
| Hypertension, n (%) | 94 (57.3%) | 7 (70.0%) | 87 (56.5%) | 0.519 |
| Hyperlipidemia, n (%) | 48 (29.3%) | 2 (20.0%) | 46 (29.9%) | 0.725 |
| Diabetes, n (%) | 25 (15.2%) | 4 (40.0%) | 21 (13.6%) | 0.047 |
| Stroke, n (%) | 8 (4.9%) | 1 (10.0%) | 7 (4.6%) | 0.923 |
| Previous history of DVT, n (%) | 5 (3.1%) | 0 (0.0%) | 5 (3.3%) | 0.727 |
| Chronic heart failure, n (%) | 19 (11.6%) | 0 (0.0%) | 19 (12.3%) | 0.607 |
| Ischemic heart disease, n (%) | 11 (6.7%) | 0 (0.0%) | 11 (7.1%) | 0.489 |
| Atrial fibrillation, n (%) | 9 (7.9%) | 0 (0.0%) | 9 (5.8%) | 0.427 |
| Hb (g/dl) | 10.2 (9.9–10.5) | 9.6 (8.2–11.0) | 10.8 (10.5–11.1) | 0.036 |
| Plt (×104/mm3) | 23.4 (22.2–24.6) | 20.2 (16.3–24.1) | 23.6 (22.4–24.8) | 0.221 |
| D-dimmer (μg/ml) | 7.6 (6.5–8.7) | 12.8 (6.3–19.2) | 7.2 (6.0–8.5) | 0.007 |
| Cre (mg/dl) | 0.58 (0.55–0.61) | 0.64 (0.50–0.79) | 0.62 (0.59–0.66) | 0.783 |
| Use of oral antiplatelet drug, n (%) | 24 (14.6%) | 1 (10.0%) | 23 (14.9%) | 0.554 |
| Use of oral steroid therapy, n (%) | 12 (7.3%) | 0 (0.0%) | 12 (7.8%) | 0.457 |
| DVT-related symptom, n (%) | 7 (4.3%) | 1 (10.0%) | 6 (3.9%) | 0.362 |
| HAS-BLED score | 1.8 (0.1–1.6) | 3 (2.3–3.7) | 1.7 (1.6–1.8) | <0.001 |
In patients with bleeding events, body mass index and hemoglobin were significantly lower, whereas D-dimer and HAS-BLED scores were significantly greater.
DOAC: direct oral anticoagulant; DVT: distal deep vein thrombosis; Hb: hemoglobin; Plt: platelet; Cre: creatinine